Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 3/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.45 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | PPARD | Q03181 | 3/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | CETP | P11597 | 2/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011680 | 0.86 | FDFT1 (0.46) | FDFT1CETP | |
| SCHEMBL10867669 | 0.85 | CETP (0.52) | FDFT1CETP | |
| SCHEMBL30677804 | 0.84 | MAPK1 (0.64) | MAPK1 | |
| SCHEMBL11197033 | 0.84 | FFAR1 (0.46) | PPARGPPARDPPARA | |
| SCHEMBL1009588 | 0.84 | MAPK1 (0.64) | MAPK1 | |
| SCHEMBL11203507 | 0.83 | THRB (0.39) | FDFT1PPARGPPARDPPARAACP3 | |
| SCHEMBL29427108 | 0.83 | ACP3 (0.60) | ACP3MEN1KMT2A | |
| SCHEMBL1832383 | 0.83 | ACP3 (0.60) | ACP3MEN1KMT2A | |
| SCHEMBL1012957 | 0.80 | CYP3A4 (0.44) | MAPK14 | |
| SCHEMBL13705084 | 0.80 | CHRM2 (0.47) | MAPK14CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044052-B2 | Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis | PFIZER INC. (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2076508-B1 | BIARYL ETHER UREA COMPOUNDS | PFIZER PROD INC (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2076508-A2 | BIARYL ETHER UREA COMPOUNDS | Pfizer Products Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20080261941-A1 | Biaryl Ether Urea Compounds | Jazz Pharmaceuticals Therapeutics, Inc. | 2008-10-23 | — | — | US | disclosed |
| WO-2008047229-A2 | BIARYL ETHER UREA COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261941-A1 | Biaryl Ether Urea Compounds | FAAH, FAAH2, LIPC | FDFT1 486/4885MAPK14 3208/4885PPARG 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.